Shots:Myra Vision received the US FDA conditional IDE approval to initiate its ADAPT study evaluating Calibreye Titratable Glaucoma Therapy (TGT) surgical system for glaucomaThe IDE trial will evaluate the safety and efficacy of Calibreye TGT surgical system in ~70 refractory glaucoma pts with 12mos. primary effectiveness endpointCalibreye System allows ophthalmologists to control…

NEWS

Roche Launches Elecsys PRO-C3 Test for Liver Fibrosis Severity Assessment

Shots:Roche has launched its Elecsys PRO-C3 test, developed with Nordic Bioscience to evaluate the severity of liver fibrosis in pts showing signs of metabolic dysfunction–associated steatotic liver disease Elecsys PRO-C3 test requires a single assay & in combination with ADAPT formula (incl. PRO-C3 levels, platelet count, age, & diabetes status) provides clear assessment of…

ByRidhi RastogiMay 6, 2025

TOP 20

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology- neuroscience- oncology- rare diseases- and plasma-derived therapies. This article is based on the 2018…

ByPrince GiriSeptember 27, 2019

Myra Vision Receives FDA Conditional IDE Approval for Calibreye TGT System to Treat Glaucoma

Roche Launches Elecsys PRO-C3 Test for Liver Fibrosis Severity Assessment

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

Contact US

OUR INFORMATION

FOLLOW US